{"title":"紫丁香素通过ESR1/PRDM2轴缓解乳腺癌细胞诱导的大鼠骨癌疼痛。","authors":"Yueping Chen, Xianhong Zhang, Jinfeng Yang, Junjun Li, Chunhui Huang","doi":"10.4196/kjpp.24.303","DOIUrl":null,"url":null,"abstract":"<p><p>Syringetin inhibits bone metastasis in cancer, but its action in breast cancer-related bone pain is unknown. This study aims to analyze the action of Syringetin in breast cancer-related bone pain. Based on network pharmacology analysis, estrogen receptor 1 (ESR1) was identified as the core gene between Syringetin and bone pain associated with breast cancer, with the binding energy of -7.5 kcal/mol to ESR1 protein. Syringetin exhibited a dose-dependent inhibition of breast cancer cell viability, suppressed cell migration and expression of ESR1 and PRDM2 protein, and promoted cell apoptosis. In the Syringetin intervention group of rats, the bone trabeculae and cortical bone were slightly intact, along with an elevation in AS and PWT scores, a decrease expression of ESR1 and PRDM2 proteins. There was a clearly positive correlation between ESR1 protein and the GFAP, IBA1, and NeuN levels. Syringetin alleviated the disease characteristics of breast cancer-related bone pain by downregulating the ESR1/PRDM2 proteins.</p>","PeriodicalId":54746,"journal":{"name":"Korean Journal of Physiology & Pharmacology","volume":" ","pages":"497-508"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198449/pdf/","citationCount":"0","resultStr":"{\"title\":\"Syringetin relieves bone cancer pain in rats induced by breast cancer cells through the ESR1/PRDM2 axis.\",\"authors\":\"Yueping Chen, Xianhong Zhang, Jinfeng Yang, Junjun Li, Chunhui Huang\",\"doi\":\"10.4196/kjpp.24.303\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Syringetin inhibits bone metastasis in cancer, but its action in breast cancer-related bone pain is unknown. This study aims to analyze the action of Syringetin in breast cancer-related bone pain. Based on network pharmacology analysis, estrogen receptor 1 (ESR1) was identified as the core gene between Syringetin and bone pain associated with breast cancer, with the binding energy of -7.5 kcal/mol to ESR1 protein. Syringetin exhibited a dose-dependent inhibition of breast cancer cell viability, suppressed cell migration and expression of ESR1 and PRDM2 protein, and promoted cell apoptosis. In the Syringetin intervention group of rats, the bone trabeculae and cortical bone were slightly intact, along with an elevation in AS and PWT scores, a decrease expression of ESR1 and PRDM2 proteins. There was a clearly positive correlation between ESR1 protein and the GFAP, IBA1, and NeuN levels. Syringetin alleviated the disease characteristics of breast cancer-related bone pain by downregulating the ESR1/PRDM2 proteins.</p>\",\"PeriodicalId\":54746,\"journal\":{\"name\":\"Korean Journal of Physiology & Pharmacology\",\"volume\":\" \",\"pages\":\"497-508\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198449/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Korean Journal of Physiology & Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4196/kjpp.24.303\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Korean Journal of Physiology & Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4196/kjpp.24.303","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Syringetin relieves bone cancer pain in rats induced by breast cancer cells through the ESR1/PRDM2 axis.
Syringetin inhibits bone metastasis in cancer, but its action in breast cancer-related bone pain is unknown. This study aims to analyze the action of Syringetin in breast cancer-related bone pain. Based on network pharmacology analysis, estrogen receptor 1 (ESR1) was identified as the core gene between Syringetin and bone pain associated with breast cancer, with the binding energy of -7.5 kcal/mol to ESR1 protein. Syringetin exhibited a dose-dependent inhibition of breast cancer cell viability, suppressed cell migration and expression of ESR1 and PRDM2 protein, and promoted cell apoptosis. In the Syringetin intervention group of rats, the bone trabeculae and cortical bone were slightly intact, along with an elevation in AS and PWT scores, a decrease expression of ESR1 and PRDM2 proteins. There was a clearly positive correlation between ESR1 protein and the GFAP, IBA1, and NeuN levels. Syringetin alleviated the disease characteristics of breast cancer-related bone pain by downregulating the ESR1/PRDM2 proteins.
期刊介绍：
The Korean Journal of Physiology & Pharmacology (Korean J. Physiol. Pharmacol., KJPP) is the official journal of both the Korean Physiological Society (KPS) and the Korean Society of Pharmacology (KSP). The journal launched in 1997 and is published bi-monthly in English. KJPP publishes original, peer-reviewed, scientific research-based articles that report successful advances in physiology and pharmacology. KJPP welcomes the submission of all original research articles in the field of physiology and pharmacology, especially the new and innovative findings. The scope of researches includes the action mechanism, pharmacological effect, utilization, and interaction of chemicals with biological system as well as the development of new drug targets. Theoretical articles that use computational models for further understanding of the physiological or pharmacological processes are also welcomed. Investigative translational research articles on human disease with an emphasis on physiology or pharmacology are also invited. KJPP does not publish work on the actions of crude biological extracts of either unknown chemical composition (e.g. unpurified and unvalidated) or unknown concentration. Reviews are normally commissioned, but consideration will be given to unsolicited contributions. All papers accepted for publication in KJPP will appear simultaneously in the printed Journal and online.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
